Farletuzumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Farletuzumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized
TargetFR-alpha
Clinical data
Routes of
administration
Intravenous injection
ATC code
  • none
Identifiers
CAS Number
  • 896723-44-7 ☒N
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6466H9928N1716O2020S42
Molar mass145371.06 g·mol−1
 ☒NcheckY (what is this?)  (verify)

Farletuzumab (MORAb-003) is a humanized monoclonal antibody[1] of IgG1/κ[2] which is being investigated for the treatment of ovarian cancer.[3][4]

This drug was developed by Morphotek, Inc.

It is targeted at folate receptor alpha (FRα) which is overexpressed in some cancers such as epithelial ovarian cancer (EOC) and non-small-cell lung carcinoma.[2]

Mechanism of action[edit]

Farletuzumab uses the following mechanisms of action:[2]

  • Antibody-dependent cellular cytotoxicity
  • Complement-dependent cytotoxicity
  • Inhibition of interaction between FRα and Lyn kinase
  • Induces cell death associated with autophagy

Adverse effects[edit]

Common adverse effects include hypersensitivity reactions, fever, chills, headache, fatigue, and diarrhea.[2]

References[edit]

  1. ^ Statement On A Nonproprietary Name Adopted By The Usan Council - Farletuzumab, American Medical Association.
  2. ^ a b c d Sato S, Itamochi H (2016-03-07). "Profile of farletuzumab and its potential in the treatment of solid tumors". OncoTargets and Therapy. 9: 1181–8. doi:10.2147/OTT.S98242. PMC 4789847. PMID 27022278.
  3. ^ Clinical trial number NCT00738699 for "Phase II Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer" at ClinicalTrials.gov
  4. ^ Clinical trial number NCT00849667 for "Phase III Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse" at ClinicalTrials.gov